PMID: 11328787May 1, 2001Paper

Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia

The Journal of Antimicrobial Chemotherapy
H F KennedyJ R Michie

Abstract

This study investigated the antibiotic susceptibilities of 67 isolates of viridans streptococci from 61 cases of bacteraemia in immunocompromised paediatric patients with malignancy. The majority of patients (87%) had received prior courses of empirical antibiotic therapy, which consisted of ceftazidime plus amikacin during period 1 and piperacillin/tazobactam plus amikacin during period 2. Susceptibility to vancomycin and quinupristin/dalfopristin was 100%. Susceptibility to beta-lactam antibiotics varied. For period 1, the geometric mean MICs of all beta-lactams tested against blood culture isolates (n = 31) exceeded those against isolates (n = 36) collected from blood after the change in empirical therapy (by 3.3-fold for ceftazidime, 2.8-fold for piperacillin/tazobactam and 1.6-fold for penicillin). The selection of a beta-lactam antibiotic for empirical therapy must be made with care, as repeated courses of certain agents may be more likely to select for viridans streptococci with diminished susceptibility.

References

May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J CarrataláF Gudiol
Feb 12, 1998·Diagnostic Microbiology and Infectious Disease·M Tuohy, J A Washington
Aug 25, 1999·The Journal of Antimicrobial Chemotherapy·G W Amsden

❮ Previous
Next ❯

Citations

May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Allan R Tunkel, Kent A Sepkowitz
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·Derek F J BrownUNKNOWN BSAC Working Parties on Resistance Surveillance
Apr 16, 2002·Current Opinion in Hematology·Rocio Garcia-Carbonero, Luis Paz-Ares
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·George AthanassopoulosHelen Giamarellou
Feb 25, 2009·Expert Opinion on Drug Metabolism & Toxicology·Maria F Wolf, Arne Simon
Aug 29, 2006·Seminars in Pediatric Infectious Diseases·Lauren Bruckner, Francis Gigliotti
Nov 12, 2016·Journal of Global Antimicrobial Resistance·Ronda L AkinsKelli L Palmer
Jun 15, 2004·International Journal of Antimicrobial Agents·P Cerdá ZolezziR Gómez-Lus
Jun 26, 2007·Pediatric Blood & Cancer·Anne F Reilly, Beverly J Lange
Jun 20, 2007·Scandinavian Journal of Infectious Diseases·Marianne LindgrenOlli Meurman
Oct 7, 2011·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·S A Sadjadi, H Ali
Sep 4, 2018·Japanese Journal of Infectious Diseases·Sevgen Tanır BasaranogluMehmet Ceyhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.